{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:16:20Z","timestamp":1781795780787,"version":"3.54.5"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Ultra-central lung cancer (UCLC) is difficult to achieve surgical treatment. Over the past few years, stereotactic ablative radiotherapy (SABR) or stereotactic body radiotherapy (SBRT) obviously improved the clinical efficacy and survival of UCLC patients. However, the adapted scheme of radiation therapy is still controversial. For this, a single arm retrospective analysis was performed on UCLC patients treated with SBRT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and Methods<\/jats:title><jats:p>We retrospectively studied primary UCLC patients who were treated with SBRT of 56 Gy\/6-8f between 2010 and 2018. UCLC was defined as planning target volume (PTV) touching or overlapping the proximal bronchial tree, trachea, esophagus, heart, pulmonary vein, or pulmonary artery within 2\u00a0cm around the bronchial tree in all directions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 58 patients whose median age was 68 years (range, 46-85) were included in our study, 79.3% of whom did not undergo any previous therapy. The median dose of the PTV was 77.8 Gy (range, 43.3-91.8), and the median PTV of tumors was 6.2 cm<jats:sup>3<\/jats:sup> (range, 12.9-265.0). With a median follow-up of 57 months (range, 6-90 months), the median cumulative overall survival (OS) rate was 58 months (range, 2-105). In addition, the 1-year, 2-year and 5-year OS rates were 94.7%, 75.0% and 45.0%, respectively. In our univariable analysis (p=0.020) and multivariate analysis (p=0.004), the OS rate was associated with the PTV. The 5-year OS rates for PTV &amp;lt;53.0 cm<jats:sup>3<\/jats:sup> and PTV \u226553.0 cm<jats:sup>3<\/jats:sup> were 61.6% and 37.4%, respectively. Regarding toxicity after SBRT, there were two cases (3.5%) with grade \u22653 adverse events, of which 1 case died of sudden severe unexplained hemoptysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patients with UCLC can benefit from SBRT at a dose of 56 Gy\/6-8f. On the other hand, smaller PTV was associated with superior outcomes, and the cure difference needs to be validated by prospective comparative trials.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.868844","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T20:38:51Z","timestamp":1651264731000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and Efficacy of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Cancer"],"prefix":"10.3389","volume":"12","author":[{"given":"Bin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengtong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeqian","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(02)04681-7","article-title":"Stereotactic Radiosurgery for Lung Tumors: Preliminary Report of a Phase I Trial","volume":"75","author":"Whyte","year":"2003","journal-title":"Ann Thorac Surg"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.06.043","article-title":"Steep Dose-Response Relationship for Stage I Non-Small-Cell Lung Cancer Using Hypofractionated High-Dose Irradiation by Real-Time Tumor-Tracking Radiotherapy","volume":"70","author":"Onimaru","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.05.034","article-title":"Clinical Outcomes of a Phase I\/II Study of 48 Gy of Stereotactic Body Radiotherapy in 4 Fractions for Primary Lung Cancer Using a Stereotactic Body Frame","volume":"63","author":"Nagata","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.10.053","article-title":"Outcomes of Risk-Adapted Fractionated Stereotactic Radiotherapy for Stage I Non-Small-Cell Lung Cancer","volume":"70","author":"Lagerwaard","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.03.073","article-title":"Stereotactic Body Radiation Therapy of Early-Stage Non-Small-Cell Lung Carcinoma: Phase I Study","volume":"63","author":"McGarry","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(16)31385-8","article-title":"Primary Study Endpoint Analysis of NRG Oncology\/RTOG 0813 Trial of SBRT for Centrally Located NSCLC","volume":"119","author":"Bezjak","year":"2016","journal-title":"Radiother Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ijrobp.2015.10.040","article-title":"Primary Study Endpoint Analysis for NRG Oncology\/RTOG 0813 Trial of Stereotactic Body Radiation Therapy (SBRT) for Centrally Located Non-Small Cell Lung Cancer (NSCLC)","volume":"94","author":"Bezjak","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B9","article-title":"Radiation Therapy Oncology Group RTOG 0813 Seamless Phase I\/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non\u2212Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients","author":"Bezjak","year":"2009","journal-title":"Update"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13105","article-title":"Outcomes and Toxicity of Stereotactic Body Radiation Therapy for Advanced Stage Ultra-Central Non-Small Cell Lung Cancer","volume":"10","author":"Cong","year":"2019","journal-title":"Thorac Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2007.n.033","article-title":"Cyberknife (R) Radiosurgery for Stage I Lung Cancer: Results at 36 Months","volume":"8","author":"Brown","year":"2007","journal-title":"Clin Lung Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(91)90249-4","article-title":"On Using the Linear-Quadratic Model in Daily Clinical-Practice","volume":"20","author":"Yaes","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.6.523","article-title":"Measuring Response in Solid Tumors: Unidimensional Versus Bidimensional Measurement","volume":"91","author":"James","year":"1999","journal-title":"J Natl Cancer Institute"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1118\/1.1774132","article-title":"Respiration Tracking in Radiosurgery","volume":"31","author":"Schweikard","year":"2004","journal-title":"Med Phys"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/02841860310013490","article-title":"Extracranial Stereotactic Radioablation - Physical Principles","volume":"42","author":"Papiez","year":"2003","journal-title":"Acta Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/JTO.0b013e31815e8577","article-title":"A Japanese Lung Cancer Registry Study - Prognosis of 13,010 Resected Lung Cancers","volume":"3","author":"Asamura","year":"2008","journal-title":"J Thorac Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-010-2072-y","article-title":"Stereotactic Body Radiotherapy for Lung Tumors at the Pulmonary Hilum","volume":"186","author":"Oshiro","year":"2010","journal-title":"Strahlentherapie Und Onkologie"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.04.014","article-title":"Stereotactic Ablative Radiotherapy (SABR) for Treatment of Central and Ultra-Central Lung Tumors","volume":"89","author":"Chaudhuri","year":"2015","journal-title":"Lung Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.03.008","article-title":"Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients With \u201cUltracentral\u201d Non-Small Cell Lung Cancer","volume":"11","author":"Tekatli","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.09.525","article-title":"Ultra-Central Tumors Treated With Stereotactic Body Radiotherapy: A Single Institutional Experience","volume":"12","author":"Yau","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.07.001","article-title":"The Safety and Effectiveness of Stereotactic Body Radiotherapy for Central Versus Ultracentral Lung Tumors","volume":"129","author":"Chang","year":"2018","journal-title":"Radiother Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14185","article-title":"Risk-Adapted Stereotactic Body Radiation Therapy for Central and Ultra-Central Early-Stage Inoperable Non-Small Cell Lung Cancer","volume":"110","author":"Meng","year":"2019","journal-title":"Cancer Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-018-01419-0","article-title":"Stereotactic Body Radiotherapy of Central Lung Malignancies Using a Simultaneous Integrated Protection Approach: A Prospective Observational Study","volume":"195","author":"Mazzola","year":"2019","journal-title":"Strahlentherapie Und Onkologie"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2021.1942545","article-title":"Ultra-Central Lung Tumors: Safety and Efficacy of Protracted Stereotactic Body Radiotherapy","volume":"60","author":"Lodeweges","year":"2021","journal-title":"Acta Oncol (Stockholm Sweden)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"J Thorac Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.868844\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T11:48:53Z","timestamp":1651751333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.868844\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":25,"alternative-id":["10.3389\/fonc.2022.868844"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.868844","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]},"article-number":"868844"}}